Metabolic syndrome, C-reactive protein, and mortality in U.S. blacks and whites: The reasons for geographic and racial differences in Stroke (REGARDS) study

Diabetes Care

Volumn 37, Issue 8, 2014, Pages 2284-2290

  Suzuki, Takeki ^a   Voeks, Jenifer ^b   Zakai, Neil A ^c   Jenny, Nancy Swords ^c   Brown, Todd M ^d   Safford, Monika M ^d   LeWinter, Martin ^c   Howard, George ^e   Cushman, Mary ^c  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d University of Alabama at Birmingham   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AFRICAN AMERICAN; ARTICLE; COHORT ANALYSIS; CRP INCORPORATED DEFINITION OF METS; DIABETES MELLITUS; DISEASE ASSOCIATION; EUROPEAN AMERICAN; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORTALITY; OBSERVATIONAL STUDY; PROTEIN BLOOD LEVEL; RACE DIFFERENCE; RATING SCALE; RISK ASSESSMENT; RISK FACTOR; AGED; BLACK PERSON; BLOOD; CAUCASIAN; EPIDEMIOLOGY; ETHNOLOGY; INCIDENCE; METABOLISM; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; STROKE; UNITED STATES; VERY ELDERLY;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INCIDENCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS; STROKE; UNITED STATES;

EID: 84904988781     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-2059     Document Type: Article

References (40)

1. McNeill AM, Katz R, Girman C.J., et al. Metabolic syndrome and cardiovascular disease in older people: The cardiovascular health study. J Am Geriatr Soc 2006; 54: 1317-1324
2. Wilson PW, D'Agostino RB, Parise H, Sullivan L., Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112: 3066-3072
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421
4. Grundy SM, Cleeman JI, Daniels S.R., et al.; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752
5. Marceau P, Biron S, Hould F.S., et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999; 84: 1513-1517
6. Hamaguchi M, Kojima T, Takeda N., et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143: 722-728
7. Hanley AJ, Williams K, Festa A., Wagenknecht LE, D'Agostino RB Jr, Haffner SM. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 2005; 54: 3140-3147
8. Chen J, Muntner P, Hamm L.L., et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004; 140: 167-174
9. Zhang L, Zuo L, Wang F., et al. Metabolic syndrome and chronic kidney disease in a Chinese population aged 40 years and older. Mayo Clin Proc 2007; 82: 822-827
10. Pasquali R, Gambineri A, Anconetani B., et al. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment. Clin Endocrinol (Oxf) 1999; 50: 517-527
11. Gami AS, Witt BJ, Howard D.E., et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49: 403-414
12. Hu G, Qiao Q, Tuomilehto J., Balkau B, Borch-Johnsen K, Pyorala K; DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164: 1066-1076
13. Ravaglia G, Forti P, Maioli F., et al. Metabolic Syndrome: prevalence and prediction of mortality in elderly individuals. Diabetes Care 2006; 29: 2471-2476
14. Hunt KJ, Resendez RG, Williams K, Haffner S.M., Stern MP; San Antonio Heart Study. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortalityin the San Antonio Heart Study. Circulation 2004; 110: 1251-1257
15. Kondo T, Osugi S, Shimokata K., et al. Metabolic syndrome and all-cause mortality, cardiac events, and cardiovascular events: a follow-up study in 25,471 young- and middle-aged Japanese men. Eur J Cardiovasc Prev Rehabil 2011; 18: 574-580
16. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and allcauses: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004; 173: 309-314
17. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28: 1769-1778
18. Katzmarzyk PT, Church TS, Blair SN Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in men. Arch Intern Med 2004; 164: 1092-1097
19. Lakka HM, Laaksonen DE, Lakka T.A., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716
20. Cesari M, Penninx BW, Newman A.B., et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003; 108: 2317-2322
21. Koenig W, Sund M, Fröhlich M, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-242
22. Ridker PM, Rifai N, Rose L., Buring JE, Cook NR. Comparison of C-reactive protein and lowdensity lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-1565
23. Tracy RP, Lemaitre RN, Psaty B.M., et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997; 17: 1121-1127
24. Cao JJ, Arnold AM, Manolio T.A., et al. Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health Study. Circulation 2007; 116: 32-38
25. Harris TB, Ferrucci L, Tracy R.P., et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999; 106: 506-512
26. Störk S., Feelders RA, van den Beld AW, et al. Prediction of mortality risk in the elderly. Am J Med 2006; 119: 519-525
27. Freeman DJ, Norrie J, Caslake M.J., et al.; West of Scotland Coronary Prevention Study. C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 2002; 51: 1596-1600
28. Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 2004; 25: 4-7
29. Fröhlich M., Imhof A, Berg G., et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 2000; 23: 1835-1839
30. Ridker PM, Buring JE, Cook N.R., Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107: 391-397
31. Wannamethee SG, Lowe GD, Shaper A.G., Rumley A., Lennon L, Whincup PH. The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older non-diabetic men. Atherosclerosis 2005; 181: 101-108
32. Ridker PM, Wilson PW, Grundy SM Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004; 109: 2818-2825
33. Suzuki T, Katz R, Jenny N.S., et al. Metabolic syndrome, inflammation, and incident heart failure in the elderly: the cardiovascular health study. Circ Heart Fail 2008; 1: 242-248
34. Howard VJ, Cushman M, Pulley L., et al. The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology 2005; 25: 135-143
35. Cushman M, McClure LA, Howard V.J., Jenny NS, Lakoski SG, Howard G. Implications of increased C-reactive protein for cardiovascular risk stratification in black and white men and women in the US. Clin Chem 2009; 55: 1627-1636
36. Pearson TA, Mensah GA, Alexander R.W., et al.; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511
37. Alberti KG, Eckel RH, Grundy S.M., et al.; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645
38. Reilly MP, Wolfe ML, Rhodes T, Girman C., Mehta N, Rader DJ. Measures of insulin resistance add incremental value to the clinical diagnosis of metabolic syndrome in association with coronary atherosclerosis. Circulation 2004; 110: 803-809
39. Rutter MK, Meigs JB, Sullivan L.M., D'Agostino RB Sr, Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 2004; 110: 380-385
40. Agarwal S, Jacobs DR Jr, Vaidya D, et al. Metabolic syndrome derived from principal component analysis and incident cardiovascular events: the Multi Ethnic Study of Atherosclerosis (MESA) and Health, Aging, and Body Composition (Health ABC). Cardiol Res Pract 2012; 2012: 919425 Stroke